No Data
No Data
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $30
Eli Lilly's Earnings Report Will Bring a Focus on Tariffs, Not Profits
Pfizer Options Spot-On: On April 30th, 219.31K Contracts Were Traded, With 3.42 Million Open Interest
Pfizer (NYSE:PFE) Reports Q1 Earnings, Reaffirms 2025 Revenue Guidance at US$61-64 Billion
SA Analyst Upgrades: PFE, ALLY, TMUS, ECC, CRK
Pfizer Analyst Ratings
orangejus : I think recent market dip told us that’s not true… Pfizer dropped by almost 20%
Deep Sea OP orangejus : Today tech stocks drop and PFE is going the opposite way. It could be due to delay in pharma tariffs and management earnings guidance for FY25 remains the same.
orangejus : Pharma tariffs being unresolved should make you very cautious about pharma stocks atm. I’m long PFE, but the recent sharp pullback of what I considered a relatively safe stock has made me reconsider my thesis.
Deep Sea OP : Dividend yield is 6.9% which is higher than bank FD. It shows that the stock is cheap and undervalued.
Deep Sea OP orangejus : Below is the tariffs actively addressed by PFE management:
"In terms of the supply chain, Pfizer is proactively addressing potential pharmaceutical tariff risks in the USA by considering shifting some overseas production back domestically. With 10 existing manufacturing bases and 2 distribution centers, Pfizer has the supply chain resilience to adjust quickly, which is a positive signal for maintaining long-term operational stability."